middle.news
SomnoMed Surges with FDA Nod and 22% Revenue Growth in FY25
12:31pm on Thursday 27th of November, 2025 AEDT
•
Healthcare
Read Story
SomnoMed Surges with FDA Nod and 22% Revenue Growth in FY25
12:31pm on Thursday 27th of November, 2025 AEDT
Key Points
FY25 revenue of $111.5 million, 22% growth exceeding guidance
EBITDA improved to $9.2 million with margin rising to 8%
FDA clearance for Rest Assure® compliance monitoring system
Manufacturing capacity increased by over 50%, backlog eliminated
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
SOM
OPEN ARTICLE